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Abstract: Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a 
majority of malignant tumors. Tumor-hypoxia leads to advanced but dysfunctional vasculariza-
tion and acquisition of epithelial-to-mesenchymal transition phenotype resulting in cell mobility 
and metastasis. Hypoxia alters cancer cell metabolism and contributes to therapy resistance 
by inducing cell quiescence. Hypoxia stimulates a complex cell signaling network in cancer 
cells, including the HIF, PI3K, MAPK, and NFĸB pathways, which interact with each other 
causing positive and negative feedback loops and enhancing or diminishing hypoxic effects. 
This review provides background knowledge on the role of tumor hypoxia and the role of the 
HIF cell signaling involved in tumor blood vessel formation, metastasis, and development of 
the resistance to therapy. Better understanding of the role of hypoxia in cancer progression will 
open new windows for the discovery of new therapeutics targeting hypoxic tumor cells and 
hypoxic microenvironment.
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Introduction
Twenty-five percent of deaths in the United States are caused by cancer, and the number 
of incidences increases due to population growth, prolonged life expectancy, and an 
abundance of risk factors including smoking, a lack of activity, and obesity.1 A common 
feature of most tumors is a low level of oxygen, called hypoxia, the severity of which 
varies between tumor types (Table 1). In intensively proliferating and expanding tumor 
tissue, oxygen demand is surpassed by oxygen supply, and the distance between cells 
and the existing vasculature increases, hampering oxygen diffusion and creating even 
more hypoxic milieu.2,3 It is generally accepted that the oxygen level in hypoxic tumor 
tissues is poorer than the oxygenation of the respective normal tissues and on average 
it is between 1%–2% O
2
 and below (Table 1). However, tumor oxygen level depends 
on the initial oxygenation of the tissue, the size and stage of the tumor, the method of 
oxygen measurement, and in which part of the heterogenic tumor tissue the measure-
ment was performed (Table 1).4–7 Tissue normoxia, also known as physoxia, is the oxy-
genation in healthy tissues, which varies widely between the organs due to diversified 
blood vessel network and metabolic activity. Oxygen concentration in humans ranges 
between approximately 9.5% O
2
 in the renal cortex7 to 4.6% O
2
 in the brain with neurons 
extremely sensitive to hypoxia.8–10 These oxygen values are far from the experimental in 
vitro conditions. The oxygen concentration commonly used in the laboratory setting is 
20.9% O
2
, which means that cell culture is performed in hyperoxic rather than physoxic 
conditions of respective organs. In order to better understand principles of oxygenation 





in vitro and in vivo, basic knowledge of the physics of gases 
is required for newcomers in the hypoxia research field which 
has been neatly described in a recently published review.11
Cancer cells respond differently to decreased oxygen-
ation leading to cell death or cell survival which partially 
depends on the time of exposure to hypoxia. The discrepancy 
and lack of consistency in experimental oncology regarding 
the definition of acute versus chronic hypoxia often with dif-
ferent biological consequences was thoroughly reviewed.12,13 
In general, it is accepted that acute hypoxia is an abrupt and 
brief exposure to short-term hypoxia which occurs when 
blood vessel occlusion lasts for at least several minutes.14 It 
is reversible and often leads to oxygen fluctuations called 
cycling hypoxia. In acute hypoxia in vitro, cells are usually 
exposed to continuous hypoxia between a few minutes and 
up to 72 hours.12 Short-term hypoxia allows cells to sur-
vive in these adverse conditions by activating autophagy, 
an apoptotic and metabolic adaptation of cells. Autophagy 
is achieved by decreasing oxidative metabolism.15,16 On 
the contrary, others have shown that cycling hypoxia led 
to increased reactive oxygen species (ROS) production, 
what contributed to tumor cell survival and progression.17,18 
Moreover, both short- and long-term hypoxia was shown 
to increase radio-resistance of cancer cells both in vitro17,19 
and in vivo.17,20 In addition, acute hypoxia was associated 
with more aggressive tumor phenotype through induction 
of spontaneous metastasis.12,21,22
Enduring changes in blood flow and low oxygen 
availability resulting in chronic hypoxia are especially 
pronounced in larger tumors and contribute to long-term 
cellular changes. In experimental settings, chronic condi-
tions are considered when the cells are incubated in hypoxia 
between a few hours and as long as several weeks.12 Longer 
exposure to hypoxia is associated with high frequency of 
DNA breaks, accumulation of DNA replication errors 
since hypoxia hampers DNA repair systems including 
homologous recombination and mismatch repair, poten-
tially leading to genetic instability and mutagenesis.23–25 Of 
note, acute hypoxia also leads to genomic instability due to 
delayed DNA damage response and rapid p53-dependent 
apoptosis.26 It was suggested that cells lacking functional 
p53 are more susceptible to genomic instability and poten-
tially tumorigenesis if they experience reoxygenation after 
acute exposure to hypoxia.26
Nonetheless, cycling hypoxia represents the situation of 
oxygenation in tumor tissues. Oxygen fluctuation occurs at 
irregular intervals in cancer with sporadic reoxygenation 
periods due to dysfunctional tumor vascularity and hetero-
genic blood supply.27,28 Undoubtedly, both chronic and acute 
hypoxic regions in tumors directly affect clinical responses to 
therapy by influencing tumor growth, ability to metastasize, 
and resistance to cell death.
Signaling pathways related  
to tumor hypoxia
Hypoxia induces a number of complex intracellular signaling 
pathways such as the major  hypoxia-inducible factor (HIF) 
pathway. Other hypoxia-associated pathways include PI3K/
AKT/mTOR,29,30 MAPK also known as ERK pathways,31–33 
and the NFĸB.34 These pathways are involved in cell pro-
liferation, survival, apoptosis, metabolism, migration, and 
inflammation.
PI3K/AKT/mTOR, MAPK, and NFĸB signaling path-
ways are also stimulated in a hypoxia-independent manner 
by a number of factors such as cytokines, chemokines, and 
growth factors which bind to receptor tyrosine kinases, 
G protein-coupled receptors, toll-like receptors (TLR), and 
alarmins receptors on the cell surface, which eventually 
may also lead to HIF-1α activation (Figure 1). In addition, 
in cancer cells epigenetic changes and acquired mutations 
of the pathways’ members and overactivation/overstimula-
tion of receptors cause uncontrollable cancer cell growth.35 
Targeting non-HIF pathways provides a promising target for 
anti-neoplastic therapy and each pathway is a vast topic on 
its own. More information regarding the role of the non-HIF 
pathways in cancer can be found elsewhere. This review will 
Table 1 Comparison of the oxygenation in organs and respective tumors
Tissue/organ Physoxia (median % O2) Reference Cancer Hypoxia (median % O2) Reference
Brain 4.6 8,9 Brain tumor 1.7 6,122
Breast 8.5 6 Breast cancer 1.5 6,123
Cervix (nullipara) 5.5 4,6 Cervical cancer 1.2 4,6
Kidney cortex 9.5 7 Renal cancer 1.3 124
Liver 4.0–7.3 125,126 Liver cancer 0.8 125,126
Lung 5.6 127 Non-small-cell lung cancer 2.2 127
Pancreas 7.5 128 Pancreatic tumor 0.3 128,129
Rectal mucosa 3.9 130 Rectal carcinoma 1.8 130
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mainly concentrate on the HIF pathway and its involvement 
in tumor progression.
HiF pathway
Cellular adaptation to hypoxia is primarily mediated by a 
family of transcriptional regulators, HIF, which was identified 
2 decades ago.36 The hypoxic induction and protein stabili-
zation of HIF-α subunits (HIF-1α, HIF-2α, and HIF-3α) 
is regulated by oxygen sensors, including PHD and FIH-1 
enzymes. PHDs and FIH-1 are upstream of HIF-α and their 
activity is oxygen-dependent.37 In oxygenated cells, HIF-α 
subunits are hydroxylated by PHDs and FIH-1, which facili-
tate the tagging of HIF-α-OH by pVHL, polyubiquitination 
and protein degradation of HIF-α by the proteasome.38 
When the oxygen level drops, the PHD enzymes lose their 
activity, the hydroxylation of the HIF-α subunit is inhib-
ited and the degradation halted. The non-hydroxylated, 
stabilized HIF-α subunits translocate to the nucleus where 
they dimerize with constitutively expressed HIF-β subunit, 
bind to DNA and initiate gene transcription of the adaptive 
pathways (Figure 1).37
Apart from hypoxia, the HIF pathway is modulated in a 
hypoxia-independent manner. HIF-α stabilization and activ-
ity is regulated by epigenetic changes and mutations, which 
lead to a loss of tumor-suppressor functions (ING4, p53, 
PTEN, VHL) and a gain of oncogene functions (Ras, Raf, Src, 
mTOR, and Myc).39–41 Hypoxia-independent HIF-α regula-
tion occurs in response to cytokines, lipopolysaccharides, and 
growth factors, mediated by PI3K/AKT/mTOR,29,30 MAPK,41 
and NFĸB pathways.42,43 In addition, mitochondrial ROS44,45 
and nitric oxide (NO)46 were shown to up- or downregulate 
HIF-1α accumulation (Figure 1).
Due to the diversified character of tumors including 
hypoxic and inflammatory phenotype, signaling pathways 
are activated simultaneously and they frequently share a 
number of target genes. HIF-1α and NFĸB together regulate 
over 1,000 genes, and thus control malignant and metastatic 



































































Normoxia and hypoxia – green
Gene expression and biological consequences – black
NO
Figure 1 Regulation of HiF in normoxic and hypoxic conditions.
Notes: HiF-α, a transcription factor, can be regulated by both hypoxic and non-hypoxic factors. in normoxia, HiF-α subunits are hydroxylated by oxygen sensors, including 
PHD and FiH-1 enzymes, causing polyubiquitination and proteasomal degradation of hydroxylated HiF-α subunits (red arrows). PHD and FiH-1’s activity is oxygen-dependent 
(red arrows); in hypoxia (blue arrows) these enzymes lose their activity due to decreased oxygenation, resulting in HiF-α protein stabilization, accumulation, and translocation 
into the nucleus resulting in gene transcription and biological consequences (black arrows). HiF is also modulated in a hypoxia-independent manner in response to nitric oxide 
(NO), reactive oxygen species (ROS), cytokines, lipopolysaccharides, and growth factors through receptor tyrosine kinases (RTK), G protein-coupled receptors (GPCRs), 
toll-like receptors (TLR) and alarmins receptors. The non-hypoxic HiF regulation is mediated by a number of different signaling pathways including NFκB, Pi3K/AKT/mTOR, 
and MAPK/eRK (green arrows). These pathways, as well as ROS production, are additionally regulated by hypoxia, which results in multiple levels of HiF-α stimulation, both 
hypoxic and normoxic. As a result, HiF accumulation and activation alters blood vessel formation, apoptosis, metastasis, and metabolism via a number of genes including 
veGF, SDF-1, Ang-2, MMPs, BNiP-3, p53, epithelial-to-mesenchymal transition (eMT), e-cad, CXCR4, LOX, CAiX, GLUT-1, and GSK (black arrows).





survival via a number of growth factors and inhibition of pro-
apoptotic pathways, ii) contribute to tumor neovascularization 
via VEGF, VEGF receptors, COX-2, iNOS, iii) regulate cell 
detachment via downregulation of adhesion molecules such as 
cadherins, and iv) induce cell migration and invasion through 
matrix degrading enzymes.43 The HIF and NFKB pathways are 
controlled by a negative feedback loop mechanism and also 
intersect via alarmins. Tissue damage and necrosis, which can 
be also induced by hypoxia, increases the presence of alarm-
ins, the endogenous markers for damage, which are recognized 
by receptor for advanced glycation endproducts (RAGE) and 
some of TLRs. In addition, the expression of RAGE recep-
tor is also upregulated by HIF-1a. In turn, alarmin receptors 
strongly activate NFkB and proinflammatory gene expression. 
Moreover, the basal HIF-1a mRNA expression is regulated by 
NFKB in non-hypoxic conditions since HIF-1a promoter was 
shown to be responsive to certain NFKB subunits.39
The HIF pathway is required during physiological 
processes and is implicated in cancer biology by regulat-
ing hundreds of genes.47–49 This master regulator facilitates 
tumor growth by promoting angiogenesis via VEGF and 
SDF-1,50,51 metabolism via regulation of GLUT-1, GLUT-3, 
and glycolytic enzymes,52–54 and regulating cell apoptosis 
and cell survival via BNIP-3,55 p53,56,57 TGF-β, and bFGF.3 
Moreover, HIF-α contributes to cancer metastasis by alter-
ing cancer cell adhesion and motility through regulation 
of epithelial-to-mesenchymal transition (EMT) and E-cad, 
ZEB1, -2 and TCF3 expression,58 as well as migration and 
invasion abilities through CXCR4,59 CAIX,60 LOX,61 MMP-2, 
and MMP-9.47,62,63
The role of hypoxia in progression 
and metastasis in cancer
Pathological hypoxia is a common microenvironment factor 
in tumors that facilitates cell survival and propagation of 
the tumor. Key cellular responses to hypoxia triggered by 
overexpression of HIF-1α and HIF-2α subunits and their 
downstream targets increase blood vessel formation, aggres-
siveness, metastasis, and resistance to treatment.
Blood vessel formation
Blood vessels  create a network of tubes and capillaries which 
nourish the entire body with oxygen and nutrients. Thus, the 
way they are formed and function is crucial in embryogen-
esis and physiology. Blood vessels consists of endothelial 
cells (ECs) which create a tight barrier between the blood 
and tissue, and interact with ECM. In embryogenesis, blood 
vessels are formed de novo by vasculogenesis involving 
bone marrow-derived endothelial progenitor cells (EPCs)64 
followed by angiogenesis, a process where new blood vessels 
are created from pre-existing vasculature.65 Lastly, the vessels 
undergo maturation which includes physical interaction with 
smooth muscle cells and pericytes. Abnormal angiogenesis 
is a feature of pathological conditions including tumor 
progression, where hyperproliferating cancer cells surpass 
their blood supply and become hypoxic. Hypoxia induces the 
imbalance between pro- and anti-angiogenic factors’ produc-
tion, which leads to enhanced, rapid and chaotic blood vessel 
formation. Hypoxia and potent transcription factors HIF-1α 
and HIF-2α have been shown to be involved in all steps of 
blood vessel formation.36,64,65 i) Hypoxia and HIF-α subunits 
contribute to the EPCs’ recruitment from the bone marrow 
and induction of their differentiation into ECs by regulation 
of VEGF, a primary regulator of vasculogenesis. This is also 
mediated through stimulation of pro-angiogenic molecule 
production such as VEGF-R2 (Flk-1), members of the FGF 
family and PDGF, important in the primitive vascular network 
formation.64,66 ii) Hypoxia and HIF-α are also involved in the 
angiogenesis process by inducing enzymes’ expression (ie, 
MMPs) in order to sprout and split the pre-existing vessels. 
In turn, neovessels allows ECs to migrate in response to 
chemoattractants across ECM. Additionally hypoxia induces 
ECs’ proliferation by regulation of VEGF-R1 (Flt-1), Ang-1 
and Ang-2 expression.67 iii) Finally, hypoxia and HIF-α sup-
port vessel maturation via induction of Ang-1, PDGF, and 
TGF-β to recruit supporting cells such as smooth muscle cells 
and pericytes creating mature and stable blood vessels.67
However, in tumors, neovessels are often abnormal, 
immature, and leaky. They are either insufficient or excessive 
depending on the tumor type.65 Neovasculogenesis maintains 
blood flow to the growing tumor tissue that expands rapidly, 
providing nutrients and oxygen for thriving cancer cells; 
however, more cells means more demand causing even more 
hypoxia. Again, hypoxia in turn stimulates angiogenesis to 
ameliorate hypoxic condition, closing the vicious circle. As 
a consequence the tumor tissue ends up being highly hypoxic 
with excessive but dysfunctional vasculature.68
Folkman was the first to propose anti-angiogenic therapy 
to treat cancer in 1971.69 A successful use of monoclonal anti-
body against VEGF (bevacizumab) approved for treatment 
of metastatic colorectal cancer70 followed by multiple solid 
tumors, has stimulated development of other anti-angiogenic 
therapies. However, long-term exposure to these agents 
revealed not only reducing tumor growth, but also more 
malignant and invasive cancer phenotype increasing metas-
tasis.71 Long-term exposure to anti-angiogenic agents reduce 
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tumor; however, at the same time induce more aggresive and 
metastatic tumor phenotype.71,72
Metastasis
Enhanced angiogenesis is associated with metastasis since 
permeable and heterogeneous vasculature facilitates the 
extravasation, circulation, and relocation of tumor cells of 
tumor cells to new and unaffected tissues escaping the hostile 
hypoxic environment.68 Tumor oxygenation is a critical fac-
tor of cancer progression and the overexpression of HIF-α 
subunits in tumors and their metastases is associated with the 
aggressiveness of a majority of human cancers and correlates 
with poor overall survival.49,73,74
It was demonstrated previously that hypoxic cells are 
more aggressive and invasive with better ability to metasta-
size. For instance, multiple myeloma cancer cells cultured in 
hypoxic conditions in vitro and injected into mice were able to 
spread to the new bone marrow faster than the cells cultured 
in normoxic conditions.63,75 Also, exposing an orthotopic 
mouse model of cervical carcinoma to a dozen cycles of 10 
minutes 7% O
2
, which was followed by 10 minutes of air 
exposure daily, increased the number of lymph node metas-
tases.76 Similar observations were recorded in mice bearing 
sarcoma tumors, where exposure to acute hypoxia augmented 
the lung metastases.77
Mechanistically, hypoxia was shown to influence 
invasive and migratory behavior of cancer cells via EMT, 
a trans-differentiation of cells in order to acquire plastic and 
mobile abilities, a process which alters their gene expression 
prior to migration.78 EMT is physiologically active during 
embryogenesis and tissue regeneration, as well as in can-
cerogenesis in many types of solid tumors79 and hematologic 
malignancies.63 Hypoxia-induced EMT is characterized by 
a decrease in epithelial-associated gene expression, such 
as E-cad, β-catenin80 and an increase in mesenchymal-like 
gene expression, such as N-cad,81 vimentin, SMA,82 and 
CXCR4.63,75 EMT is promoted by a master regulator TGF-β, 
also increased by hypoxia, which activates downstream 
transcription factors such as Smads, Snail, Slug, and Twist, 
and inhibits expression of E-cad.63,83 Interestingly, radio- and 
chemoresistance was also shown to be associated with EMT 
phenotype; expression of Snail and Slug antagonizes p53-
mediated apoptosis and promotes resistance to radiation and 
chemotherapeutic agents such as paclitaxel and cisplatin in 
ovarian cancer cells.84
Moreover, HIF-1α was shown to be expressed in 90% 
of human gastric cancer biopsies at the front edge of the 
invading tumor compared to HIF-1α negative normal tis-
sues.74 HIF inhibition significantly reduced the metastasis of 
gastric cancer cells in vivo, and HIF deficient cells were less 
motile, invasive, and adhesive in vitro.74 High involvement of 
the main hypoxic regulator, HIF-α, in all steps of metastasis 
led to many trials of inhibiting this molecule to diminish 
cancer cell trafficking thus reducing metastasis. Inhibition of 
HIF-1 activity using antisense oligonucleotide (EZN-2968) 
gave effective results and a safe toxicity in a Phase I clinical 
trial in metastatic, advanced solid malignancy.85 Targeting 
hypoxic cells with a pro-drug, activated only in a hypoxic 
environment, is one of the newest and highly promising 
strategies to reduce metastasis, currently undergoing phase 
I/II clinical trials in multiple myeloma, a model of a process 
of metastasis.86
Apart from targeting HIF-α molecules, another strategy 
to inhibit metastasis is to target genes downstream of HIF-α. 
For instance, CAIX is a hypoxia-inducible enzyme widely 
present in tumors; it is crucial in regulating intra- and extra-





























































































































































Figure 2 Hypoxia as a driving force of tumor progression and metastasis.
Notes: Hypoxia stimulates tumor i) vasculogenesis through endothelial progenitor 
cells’ mobilization from the bone marrow to the tumor site by veGF, veGF-R2, 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and stromal-
derived growth factor-1 (SDF-1) and ii) angiogenesis by sprouting of the pre-existing 
vessels caused by increased production of veGF, veGF-R1, veGF-R2, Ang-1, Ang-2, 
and MMPs. New blood vessels facilitate cancer cells leaving the primary tumor site, 
which is enhanced by increased expression of lysyl oxidase (LOX), carbonic anhydrase 
iX (CAiX), MMPs, integrins, and CXCR4. Hypoxic cancer cells also undergo 
epithelial-to-mesenchymal transition (eMT) acquiring plastic and mobile phenotype 
by increasing transcription factors such as Slug, Snail, and Twist and decreasing 
expression of adhesion molecules such as β-catenin and e-cadherin (e-cad). Chemo- 
and radio-resistance of patients is caused by eMT-related stemness of cancer cells 
and hypoxia-induced cell cycle arrest in G1 phase. Hindered drug diffusion due to 
anomalous vascularity is another mechanism of chemoresistance.





cancer cells.87 It was demonstrated that, inhibition of CAIX 
decreased tumor growth and metastasis in pre-clinical breast 
tumor models.87 LOX is another protein elevated in hypoxic 
human tumor cells (such as breast, and head and neck cancer) 
and is HIF-α-dependent.61 LOX secreted by tumor cells 
accumulates at new sites and mediates bone marrow-derived 
cell recruitment which forms a “pre-metastatic niche” for 
future metastasis.88 Inhibition of LOX reduced hypoxia-
induced recruitment and metastasis in the breast cancer 
mouse model.88 Another target candidate induced by hypoxia 
in cancer cells is CXCR4 involved in cell trafficking.89,90 It 
was demonstrated that metastatic tumor cells expressing high 
levels of CXCR4 home to tissues rich in its ligand, SDF-1,63,91 
and inhibitors of CXCR4/SDF-1 axis resulted in disruption 
of the metastatic process (Figure 2).90
Radiation and drug resistance
Resistance of cancer cells to treatment-induced apoptosis is 
one of the biggest obstacles in cancer therapy.92 A vast number 
of cancer patients relapse and suffer from recurring tumors as 
a result of micro-residual disease, the resistant subpopulation 
of cancer cells, leading to local recurrence and/or metastasis.93 
Tumor hypoxia develops due to uncontrollable cell prolifera-
tion, altered metabolism, and abnormal tumor blood vessels 
resulting in reduced transport of oxygen and nutrients.13 
Hypoxia is one of the main features of solid tumors and was 
shown to correlate with poor prognosis of cancer patients.73 
While hypoxia is lethal for many cells, a subpopulation of 
tumor cells is able to not only adapt to hypoxic conditions 
but also become resistant to chemo- and radiotherapy. The 
role of hypoxia in the phenomenon of therapy resistance has 
been acknowledged for at least 60 years.94,95
Hypoxia confers treatment resistance of cancer cells by 
regulating processes such as i) inducing cell cycle arrest 
(quiescence), a state of reduced cell proliferation which pro-
tects the cells from external stress,96,97 ii) inhibiting apoptosis 
and senescence of cells, iii) controlling autophagy, p53, and 
mitochondrial activity.94,97 Apart from cellular adaptations 
influenced by hypoxia, lowered oxygenation of the tumor 
tissue confers chemoresistance by affecting iv) drug deliv-
ery and cellular uptake through associated acidity and drug 
efflux pump expression such as P-gp,98 as well as by the 
v) lack of oxygen required for the cytotoxicity of a number 
of chemotherapeutics.99
One of the most important parameters of radio-resistance 
is oxygenation, the state of cell cycle, and the nature of 
radiation, whether it is gamma, X-ray, neutron radiation, or 
linear energy transfer including alpha and beta particles.94,96 
When oxygen is abundant, the normoxic cells are sensitive 
to radiation, due to “oxygen fixation” which happens when 
available molecules of oxygen react with free radicals in 
DNA generated by ionizing radiation leading to irreversible 
DNA damage. Whereas, cells irradiated in hypoxic condi-
tions are resistant to death, due to decreased production of 
DNA radicals (which can be restored “chemical restitution”) 
caused by reduced generation of ROS and decreased DNA 
damage.95 The cell cycle phase determines the radiosensitivity 
of the tumors. It was shown that cells exposed to ionizing 
radiation are the least sensitive at the end of S phase, less 
sensitive in the G1 phase, and the most radiosensitive in the 
G2/M phase where DNA repair mechanisms are the most 
prone to malfunction.100 Hence, anticancer treatments, both 
radio- and chemotherapy, preferentially target the bulk of 
rapidly proliferating tumor cells. On the other hand, the 
cells which are most resistant to treatment are quiescent, 
low-proliferating, stem-cell-like cell fractions residing in 
the most hypoxic region.82,84,97,101 For instance, it was demon-
strated that glioblastoma cancer stem cells (CD133+) showed 
higher DNA repair and decreased apoptosis in response 
to irradiation, compared to non-stem-cell-like (CD133-) 
population.94,96,102
Hypoxia causes slow-proliferating stem-cell-like pheno-
type of cells, decreases senescence, creates chaotic and mal-
functioning blood vessels, and augments metastasis, which 
all together further induces therapy resistance.96 Currently, 
assessment of tumor oxygenation and HIF expression pattern 
helps determine tumor chemo- and radio-sensitivity.94,103 It 
was reported that head-and-neck cancer samples with high 
expression of HIF-1α and HIF-2α were more resistant to 
chemotherapy (carboplatin) compared to biopsies with low 
HIF-α expression which were chemo-sensitive.104 Patients 
with oropharyngeal cancer demonstrating high expres-
sion of HIF-1α had a lower chance to achieve complete 
remission after irradiation.103 In addition, irradiation was 
shown to induce HIF-1 activity, leading to production of 
angiogenic molecules such as VEGF which protects ECs 
from irradiation-induced apoptosis.105 Therefore HIF-1 rep-
resents a valid predictive marker and therapeutic target for 
manipulation, in combination with chemotherapeutics and 
radiotherapy, in order to sensitize the cells to treatments.73
As demonstrated by others, inactivation of HIF-1α in 
mouse embryonic fibroblasts increased their susceptibility 
to carboplatin and etoposide compared to wild-type, both 
in vitro and in vivo.106 Similarly, inhibition of HIF-2α with 
short hairpin RNA reversed the resistance to doxorubicin 
and etoposide of human clear cell renal cell cancer cells 
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(one of the most resistant tumors) by restoring p53.57 It 
was reported that treating tumor-bearing mice with HIF-1 
inhibitor (YC-1) induced radiation-induced vessel damage.105 
Similarly, treatment of glioma, squamous and pancreatic 
cancer cells with the HIF-1α inhibitor (PX-478) radio-
sensitized hypoxic cells.107 Silencing of HIF-1α with siRNA 
in mouse embryonic fibroblasts increased susceptibility to 
irradiation;106 and also, HIF-2α inhibition was shown to 
enhance radiation-induced apoptosis due to HIF-2-mediated 
increase of p53 activity and accumulation of ROS, thus DNA 
damage (Figure 2).108
Tumor microenvironment
The tumor would not thrive without the interaction, cross-
talk, and support with the tumor microenvironment including 
cellular components such as stromal cells, immune cells, ECs 
as well as non-cellular components including ECM, cyto-
kines, and other mediators.109 Thus, in hypoxic tumor tissue, 
not only cancer cells but also the tumor microenvironment 
is affected by hypoxia-inducible changes.110
Hypoxia was shown to induce metabolic and molecular 
changes in ECs, increasing expression of pro-angiogenic 
molecules, blood vessel formation, and thus providing more 
oxygen and nutrients for tumor cells. Hypoxia also regulates 
inflammatory mediators and growth factors, which then 
stimulate platelet, leukocyte, and smooth muscle cell activity. 
One of the most significant changes is increase in adhesive-
ness of ECs to neutrophils facilitating NK cell trafficking and 
local inflammatory reaction.111 Depending on the duration 
of oxygen depletion, hypoxia regulates expression of NO 
synthase expression contributing to vasoconstriction.112 Since 
blood vessels nourish tumors, targeting ECs will prevent or 
reverse tumor growth.110,113–115
Stromal cells, on the other hand, facilitate tumor growth 
and tumor dissemination mostly by regulating cancer cell 
adhesion and contributing to cell proliferation and survival. 
It was shown that hypoxia induces stromal cells to produce 
a number of factors including Ang-2, ANGPTL-4, PDGF, 
VEGF, SDF-1, LOX, and SCF (KIT-ligand), influencing ECs 
and EPCs thus promoting new blood vessel formation and 
lymphangiogenesis. Also, stromal-derived SDF-1 attracts 
cancer cells and thus facilitates metastasis.115,116
It was demonstrated that hypoxia leads to immune-
resistance and immune-suppression, which help tumor 
cells to escape from immune surveillance.117,118 Some of the 
immune-suppressive effects include: 1) shedding of immune-
recognition molecules by tumor hypoxia, which results 
in decreased sensitivity to T- and NK-mediated killing;119 
2) inhibition of T cells’ and dendritic cells’ maturation and 
cytokine production;120 3) and promotion of suppressive cells 
such as regulatory T cells and tumor-associated macrophages, 
which block immune effector cells.121
Therefore, there is an increasing importance of the 
hypoxic phenotype of stromal and immune cells in the tumor 
microenvironment providing non-cancer cells as potential 
novel targets in the fight against the tumor.110
Conclusion
Pathological hypoxia affects both cancer cells and the 
tumor microenvironment, and plays a pivotal role in the 
process of cancer progression and dissemination. Hypoxia 
regulates tumor neovascularization, metabolism, cell sur-
vival, and cell death. In addition, hypoxia contributes to 
EMT-like cancer cell migration and cancer stem-cell-like 
properties including resistance to treatment, one of the 
nightmares in the medical field. Each step of the cancer 
adaptive processes is controlled by hypoxia-activating 
transcriptional programs involving HIF, NFĸB, PI3K, and 
MAPK pathways.
Since hypoxia signifies increased tumor progression 
and aggressiveness hampering patients’ survival, direct 
and indirect methods of measuring hypoxia combined with 
clinical observations may help to predict patients’ outcome 
as well as identify patients who could benefit from hypoxia/
HIF-targeted treatments. Better understanding of hypoxic 
phenomenon and dissecting out the hypoxia-inducible 
responses and signaling pathways will grant numerous novel 
targets in the near future.
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